Why Freezer Inventory Becomes the Third Module in the MES Journey for Cell Therapy
In cell and gene therapy, the moment a batch is completed is not the end of the process.
In many ways, it is the beginning of a new phase.
The therapy moves into storage – often at ultra-low temperatures like -196°C. It may remain there for days, weeks, or even months before reaching the patient.
And during that time, one question becomes critical:
Where is this patient’s therapy, and is it still viable?
The Gap Between Manufacturing and Storage
Over the past two decades, a clear pattern has emerged in how organizations approach digital transformation in GMP environments.
The journey often starts with Electronic Batch Records (EBR) to digitize manufacturing processes. Then comes scheduling, to coordinate resources, timelines, and capacity.
Both are essential.
But they stop at the point where manufacturing ends.
In reality, the therapy journey continues.
Once a batch is completed, it enters a highly sensitive storage phase where temperature control, location accuracy, and traceability are just as important as manufacturing precision.
Yet many organizations still rely on spreadsheets, manual logs, or disconnected systems to manage freezer inventory.
This creates a critical gap.
Why Freezer Inventory Is More Than Storage
Freezer inventory in cell therapy is not just about “where something is stored.”
It is about maintaining Chain of Identity (COI) and Chain of Custody (COC) beyond manufacturing.
Every therapy is patient-specific. Every vial represents a single patient’s treatment.
If visibility is lost – even temporarily, it introduces operational delays, compliance challenges, and potential risks to patient safety.
Traditional inventory systems were not designed for this level of complexity.
They lack:
- Real-time traceability across storage locations
- Integration with manufacturing and quality systems
- Automated SOP enforcement aligned with GMP requirements
- Audit-ready documentation for FDA compliance
The result?
Organizations spend valuable time reconciling records, verifying locations, and preparing for audits, often under pressure.
The Emergence of the Third Module
This is where freezer inventory naturally becomes the third module in the MES journey.
Not as an add-on. But as a continuation of the therapy lifecycle.
EBR answers: What happened during manufacturing?
Scheduling answers: When and where will it happen?
Freezer inventory answers: Where is the therapy now, and what is its current state?
Together, they create a continuous thread of traceability.
This continuity is essential for maintaining FDA compliance across the biologic lifecycle, ensuring adherence to GMP and SOP-driven processes, preserving sample integrity and viability, and supporting audit readiness with complete documentation.
Without this third module, the Chain of Identity and Chain of Custody effectively pause at the freezer door.
Industry Challenges Worth Noting
Across CMOs, CDMOs, and biotech organizations, a few recurring challenges stand out:
Fragmented Systems – Manufacturing, storage, and quality often operate in separate platforms, creating data silos. This is one of the reasons why modular software architecture is becoming essential for cell therapy operations – organizations need systems that connect rather than isolate.
Manual Intervention – Teams rely on human checks for location verification and temperature monitoring, increasing the chance of error.
Audit Complexity – Preparing for FDA inspections requires pulling data from multiple sources, which is time-consuming and prone to gaps.
Limited Visibility – Operations and quality teams lack a single source of truth for inventory status and history.
These challenges are not due to lack of effort. They stem from systems that were not built for end-to-end therapy orchestration.
How PragLife Extends Traceability into Storage
At Pragmatrix, our team has had the opportunity to work alongside organizations navigating these exact challenges.
One insight has remained consistent:
Traceability cannot stop at manufacturing. It must extend through storage and beyond.
PragLife was designed with this principle in mind.
As a modular platform built for GMP environments, it allows organizations to extend their digital journey seamlessly from EBR and scheduling into freezer inventory management.
Here’s how it supports this transition:
End-to-End COI and COC Tracking – Maintains patient-specific identity and custody across manufacturing, storage, and retrieval.
Real-Time Inventory Visibility – Provides a unified view of freezer locations, sample status, and history.
SOP-Aligned Automation – Ensures every action in storage follows predefined, validated procedures.
FDA-Compliant Audit Trails – Captures every interaction with complete traceability aligned with regulatory expectations.
Configurable Modular Architecture – Allows organizations to adopt freezer inventory as the next step without disrupting existing validated systems.
This approach helps organizations move from fragmented workflows to a more connected, compliant, and patient-centric operation.
Closing the Traceability Gap
The cell therapy industry continues to evolve toward more personalized, distributed, and time-sensitive treatments.
As this happens, the expectations around compliance, visibility, and patient safety continue to rise.
Freezer inventory is no longer a supporting function. It is a critical extension of the therapy lifecycle.
By treating it as the third module in the MES journey, organizations can close the traceability gap that exists between manufacturing and delivery.
The result is not just operational efficiency.
It is greater confidence – for quality teams, for regulators, and most importantly, for the patients waiting at the end of the supply chain.
If your organization is exploring how to extend traceability beyond manufacturing, we’re always open to a conversation on how PragLife might support that journey.
